Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic impact of Duchenne muscular dystrophy on families
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Duchenne muscular dystrophy

Economic impact of Duchenne muscular dystrophy on families

1 evidence topic · 1 source

Annual productivity-cost estimates

“the mean per-patient annual indirect (productivity) cost between $400 and $48,390.” (opens the source at this quote in a new tab)